Patheon Appoints Michel Lagarde President
PTSM: Pharmaceutical Technology Sourcing and Management
Lagarde will be based out of the company’s Boston office and will lead Patheon’s global corporate and cross-enterprise operations.
On May 31, 2016, Patheon announced that it has appointed Michel Lagarde president of the company. Lagarde will be based out of the company’s Boston office and will lead global corporate and cross-enterprise operations. He will report to the Patheon CEO, James Mullen. Mullen will continue to direct the company’s global growth strategy and oversee its business segments, sales and marketing, and quality functions.
Lagarde joins Patheon from JLL Partners, a middle market private equity firm. For the past eight years, he has been working with several of JLL’s portfolio companies, including Patheon, in the healthcare and pharma services sectors as managing director. He has served as a member of Patheon’s Board of Directors since 2011. As a result of his appointment, Lagarde has stepped down from his position on Patheon’s Board of Directors.
Source: Patheon
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Drug Solutions Podcast: Emerging Methods of Vaccine Administration and Distribution
June 20th 2023Michael Schrader, CEO and co-founder of Vaxess, discusses the latest on vaccine administration and different ways the pharmaceutical industry can distribute these products with Pharmaceutical Technology editor Jill Murphy.
FDA Grants Full Approval for Symptomatic Tenosynovial Giant Cell Tumor Treatment
February 18th 2025Tenosynovial giant cell tumor (TGCT) is rare and non-malignant, forming in or near joints, but which if left untreated can cause damage to joints and surrounding tissue, potentially leading to significant disability.
